Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. 

Biotechnology

Bolt Biotherapeutics

Randall Schatzman

Arthur Lee

Husein Hadeiba

Coya Tapia

Dawn Colburn

Senita Greene

Willie Quinn

Lynn Ferguson Lewis

Geoff W.

Aldwin Aldana Ms, Rqap-Glp, Mrqa

Pam Howland

Tai Yu

Nathan Ihle

Grant Yonehiro

Michael N. Alonso

Wesley Burwell

Lu Xu

Sarah Nemec

The leadership team at Bolt Biotherapeutics has experience in clinical development, immuno-oncology, program direction, oncology early development, and clinical pharmacology. They each have different educational backgrounds including molecular genetics from Washington University School of Medicine.

Leadership Team

Board of Directors

CEO and Executive Team

Leadership Team

About

Team members

Other teams at Bolt Biotherapeutics

Board of Directors

CEO and Executive Team